Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)
China · Delayed Price · Currency is CNY 9.83
-0.15 (-1.50%)
Apr 28, 2026, 3:00 PM CST
SHA:600867 Revenue
In the year 2025, Tonghua Dongbao Pharmaceutical had annual revenue of 2.95B CNY with 46.66% growth. Tonghua Dongbao Pharmaceutical had revenue of 767.64M in the quarter ending December 31, 2025, with 36.62% growth.
Revenue
2.95B
Revenue Growth
+46.66%
P/S Ratio
6.48
Revenue / Employee
864.29K
Employees
3,410
Market Cap
19.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.95B | 937.71M | 46.66% |
| Dec 31, 2024 | 2.01B | -1.07B | -34.66% |
| Dec 31, 2023 | 3.08B | 296.96M | 10.69% |
| Dec 31, 2022 | 2.78B | -489.44M | -14.98% |
| Dec 31, 2021 | 3.27B | 375.73M | 12.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 14.85B |
| China Resources Double-Crane Pharmaceutical | 10.73B |
| Apeloa Pharmaceutical Co.,Ltd | 9.50B |
| Betta Pharmaceuticals | 3.73B |
| Walvax Biotechnology | 2.40B |
| Jilin Aodong Pharmaceutical Group | 2.34B |
| Wedge Industrial | 1.32B |
| Wanbangde Pharmaceutical Holding Group | 1.14B |